Group items tagged

The National Health Service will begin its autumn Covid vaccine program next week, a month earlier than planned in response to the spread of a new variant dubbed Pirola. Covid vaccines will be administered to care home residents and housebound individuals from Monday onwards, while over-65s and other vulnerable groups will receive their appointments the week after. On Aug. 30, NHS England shifted the autumn vaccination drive to start on September 11 in response to the new Covid-19 variant, BA.2.86, detected on August 18. The primary groups can book through a national system upon receiving an invitation from the NHS. Some people may get an earlier call from their GP, and a few have already scheduled Covid vaccinations alongside their flu jabs. The NHS will begin inviting other eligible groups from Sept. 18. However, it is important to note that not everyone will receive a call at the same time. These groups will include individuals aged 65 and over, those aged six months to 64 years in a clinical risk category, frontline health and social care workers, and individuals aged 12 to 64 who are carers or household contacts of those with immunosuppression.

Lapses in strategies to tackle COVID-19 this year continue to create the perfect conditions for a deadly new variant to emerge, as parts of China witness a rise in infections, the head of the World Health Organization said on Friday (December 2). The comments by WHO Director-General Tedros Adhanom Ghebreyesus mark a change in tone just months after he said that the world has never been in a better position to end the pandemic. "We are much closer to being able to say that the emergency phase of the pandemic is over, but we're not there yet," Tedros said on Friday. The global health agency estimates that about 90% of the world's population now has some level of immunity to SARS-COV-2 either due to prior infection or vaccination. "Gaps in testing … and vaccination are continuing to create the perfect conditions for a new variant of concern to emerge that could cause significant mortality," Tedros said. COVID-19 infections are at record highs in China and have started to rise in parts of Britain after months of decline.

British drugmaker AstraZeneca says it's confident that its new version of COVID-19 antibody treatment could protect immunocompromised patients against all known virus variants. Laboratory studies show the antibody, called AZD3152, neutralises all known variants of COVID-19 and AstraZeneca has support from regulators to make the treatment available by the end of this year, the company's vaccines head Iskra Reic said on Tuesday (April 18). AstraZeneca plans, pending more positive data and regulatory approval, to make the antibody available by the end of 2023. These types of therapies are most needed for people with compromised immune systems, either because of underlying conditions or because they are undergoing immune suppressing treatments. They account for nearly 2% of the global population. AstraZeneca's AZD3152, it new COVID-19 antibody, was acquired through a $157 million deal last year with British biotech start-up RQ Bio. The British drugmaker will likely make future investments like its current partnerships with RQ Bio but did not have any deals to announce, said Reic, a long-time AstraZeneca executive who has led the company's vaccines and immune therapies unit since it was formed in late 2021, during the pandemic.

There is a realistic possibility of large waves of Covid-19 infection in the future in Britain and such waves might even be considered likely, epidemiologists who model the Covid-19 pandemic to inform government advice have said. Prime minister Boris Johnson has ditched legal restrictions in England, saying that, while the pandemic was not over, Britain needs to learn to live with Covid. The Scientific Pandemic Influenza Group on Modelling, Operational sub-group (SPI-M-O) said the emergence of new viral variants was the biggest unknown factor in the medium-to-long term, along with waning population immunity and changes in mixing patterns. "Large future waves of infection that need active management to prevent detrimental pressure on the health and care sector are, at least, a realistic possibility (high confidence) or likely (medium confidence)," SPI-M-O said in a consensus statement published on Friday.

The Pharmacists' Defence Association (PDA) has urged pharmacists working in Covid-19 vaccination role to report any concerns about the needles and syringes supplied with the Moderna Spikevax Bivalent vaccine. The association has heard reports of bending when vaccinators pierce the top of the vial containing the Covid-19 vaccine doses, needles falling out during manipulation and appearing to be bent even before removal from the packaging. PDA has advised its members who are working in a Covid-19 vaccination role "to report any concerns via the Yellow Card medical device reporting system, and to keep up to date with NHS clinical updates for ongoing information and guidance." Current advice from the NHS includes sharing of video and poster resources (available on FutureNHS) which have been produced by the supplier to support the introduction of the new administration needles and syringes for Spikevax Bivalent. This is following a switch from BD Flu+ 23G x 25mm 1ml syringe combined needle and syringe (CNS) to the Owen Mumford Unifine Safety Retractable Needle 25G x 25mm & 1ml Syringe.

A community pharmacist, Viral Doshi was honoured with the British Citizen Award (BCA) on Thursday (26 January) at the Palace of Westminster for transforming his community centre into vaccination hub during Covid-19 pandemic. Viral was presented with his Medal of Honour by Liam Sargeant, Senior Company Communications Manager, from supporters P&G and TV presenter and Patron of the BCA, Nick Knowles, who hosted the event. At the height of the pandemic, Viral obtained approval to transform his community centre into a vaccination hub. Located in the heart of a multi-ethnic population, with social deprivation, surrounded by wards experiencing high rates of Covid-19. His determination to increase uptake and reduce vaccination hesitancy, led to 80,000 vaccinations being administered, the overall highest vaccination uptake in North West London. Viral is a passionate advocate for the role that GP practices and community pharmacies can play in supporting the health agenda. His objective, to provide better choice and access for the community have been fully met and appreciated by patients. His initiatives led to a dramatic increase in the clinical skills, knowledge and services offered by local community pharmacies around a variety of health topics. This enabled pharmacies to adopt a holistic health approach to working with their communities.

NHS England has urged the pharmacy owners to continue to voluntarily submit New Medicine Service (NMS) quarterly summary data to the NHS Business Services Authority (NHSBSA) for Quarter 4 (Q4) 2022/23 (January to March 2023). Community Pharmacy England have agreed with NHS England that the quarterly returns will continue to be on a voluntary basis, with Q4 (January to March 2023) as the second quarter to be reported. It has thanked all the members that submitted NMS quarterly summary data for Quarter 3. The mandatory requirement to submit this data has been suspended since 2020, due to the COVID-19 pandemic. "NHS England wants to continue collection of the quarterly returns to provide baseline data to support a long-term evaluation that will be conducted as part of ongoing work to expand the scope of NMS," said Community Pharmacy England. Voluntary submissions can be made via the NHSBSA website, where an updated reporting spreadsheet is also available for head offices to use who are able to submit data on behalf of multiple pharmacies.

The British Generic Manufacturers Association (BGMA) has elected Diane DiGangi Trench to be its new vice-chair. DiGangi Trench takes up the position replacing Xiromed's Peter Ballard and in 12-months' time will assume the association's chair role from Accord's Peter Kelly. With over 25 years of pharmaceutical industry experience, DiGangi Trench has held a number of senior commercial roles including stints with Takeda and Astra Zeneca. She joined Sandoz in 2018 in the US, where she served as Vice-President, Market Access and Patient Services. In 2021, she became the head of Sandoz' UK business and in her two years in role, she has led the organisation through a post-COVID recovery and growth phase to prepare for the proposed spin out of the company from its parent, Novartis, expected later this year. She said: "It's a great honor to take on the role of Vice Chair of the BGMA. The success of the generics and biosimilar industry is essential to the functioning of the NHS. Generic medicines fill four out of five UK prescriptions and biosimilars enable the NHS to expand access to more patients. I am passionate about increasing the sustainability of our industry so we can continue to play our vital part in the health of the nation." Mark Samuels, BGMA chief executive, said: "We are extremely fortunate to be able to call upon the expertise of Diane who has already added significant value through her role on the BGMA board and leadership of a key strategic committee.

In his maiden speech delivered to community pharmacy since becoming new minister with responsibility for the sector, Will Quince MP said he's determined to be "your champion" and "voice in government". Addressing delegates on Wednesday (Oct 12) as chief guest at the 22nd Pharmacy Business Awards in central London, he praised community pharmacy for delivering 25 million Covid-19 vaccines, five million flu jabs, 200 million lateral flow testing kits and millions of medicines throughout the pandemic. "These local efforts became the national success story," he told over 600 attendees at a gala dinner held at the iconic Park Plaza Westminster Bridge hotel overlooking the Houses of Parliament. 'We need you now' Quince, who was appointed minister of state at the Department of Health and Social Care on 7 September 2022, added: "Just as we needed you in the pandemic, we need you now," highlighting the vital role of community pharmacy in realising the secretary of state (Thérèse Coffey)'s vision, particularly in regard to her much talked about 'Plan for Patients'.

Polio has been detected in sewage samples in London, the first sign since the 1980s that the virus could be spreading in the UK, but no cases have been found, authorities said. The risk of infection from the disease, which causes paralysis in children in under one per cent of cases, was also low because of high vaccination rates, the UK Health Security Agency (UKHSA) said. The agency nevertheless encouraged parents to make sure their children were vaccinated after the discovery of the virus during routine wastewater surveillance - particularly those who may have missed shots during the Covid-19 pandemic. Nationwide vaccination levels are above the 90 per cent needed to prevent outbreaks, but London's coverage rates among the under-twos has dipped below that in recent years. NHS England will begin contacting parents of children under five who are not immunised. Polio, spread mainly through contamination by faecal matter, used to kill and paralyse thousands of children annually worldwide. There is no cure, but vaccination brought the world close to ending the wild, or naturally occurring, form of the disease.

Lord Markham, a health minister suggested the House of Lords on Tuesday (10 January) that plan of 'using pharmacies more for patient will put funding their way', just like allocation of Covid vaccine provided support. In a statement to the House of Lords he praised the sector saying they are a 'crucial part of the front line'. His statement was in response to a question from Lord Grade, who is campaigning on behalf of the community pharmacy sector. Lord Grade warned Government that it must take action before pharmacies start to close. On Monday (9 January) the Health Secretary, Steve Barclay MP, commented: "There are many more things that community pharmacists can support with that can ease pressure on General Practice. The Primary Care recovery plan will set out a range of additional services that Community Pharmacy can deliver."